Availability of and Access to Orphan Drugs
- 830 Downloads
Background: Market authorization does not guarantee patient access to any given drug. This is particularly true for costly orphan drugs because access depends primarily on co-payments, reimbursement policies and prices. The objective of this article is to identify differences in the availability of orphan drugs and in patient access to them in 11 pharmaceutical markets: Australia, Canada, England, France, Germany, Hungary, the Netherlands, Poland, Slovakia, Switzerland and the US.
Methods: Four rare diseases were selected for analysis: pulmonary arterial hypertension (PAH), Fabry disease (FD), hereditary angioedema (HAE) and chronic myeloid leukaemia (CML). Indicators for availability were defined as (i) the indications for which orphan drugs had been authorized in the treatment of these diseases; (ii) the application date; and (iii) the date upon which these drugs received market authorization in each country. Indicators of patient access were defined as (i) the outcomes of technology appraisals; (ii) the extent of coverage provided by healthcare payers; and (iii) the price of the drugs in each country. For PAH we analysed bosentan, iloprost, sildenafil, treprostinil (intravenous and inhaled) as well as sitaxentan and ambrisentan; for FD we analysed agalsidase alfa and agalsidase beta; for HAE we analysed icatibant, ecallantide and two complement C1s inhibitors; for CML we analysed imatinib, dasatinib and nilotinib.
Results: Most drugs included in this study had received market authorization in all countries, but the range of indications for which they had been authorized differed by country. The broadest range of indications was found in Australia, and the largest variations in indications were found for PAH drugs. Authorization process speed (the time between application and market authorization) was fastest in the US, with an average of 362 days, followed by the EU (394 days). The highest prices for the included drugs were found in Germany and the US, and the lowest in Canada, Australia and England. Although the prices of all of the included drugs were high compared with those of most non-orphan drugs, most of the insurance plans in our country sample provided coverage for authorized drugs after a certain threshold.
Conclusions: Availability of and access to orphan drugs play a key role in determining whether patients will receive adequate and efficient treatment. Although the present study showed some variations between countries in selected indicators of availability and access to orphan drugs, virtually all of the drugs in question were available and accessible in our sample. However, substantial co-payments in the US and Canada represent important barriers to patient access, especially in the case of expensive treatments such as those analysed in this study.
Market exclusivity is a strong instrument for fostering orphan drug development and drug availability. However, despite the positive effect of this instrument, the conditions under which market exclusivity is granted should be reconsidered in cases where the costs of developing an orphan drug have already been amortized through the use of the drug’s active ingredient for the treatment of a common indication.
KeywordsChronic Myeloid Leukaemia Pulmonary Arterial Hypertension Fabry Disease Orphan Drug Ambrisentan
This study was supported by a research grant from the Federal Ministry for Research and Education in Germany (grant number: BMBF 01FG09007). The sponsor had no role in the study design, collection and analysis of data, the writing of the report or the submission of the paper for publication. In addition, the authors would like to thank the Munich Center of Health Sciences (MC-Health) for interesting discussions and helpful comments. Finally, the authors want to express their gratitude to the very helpful and supportive comments of the three anonymous reviewers.
The authors have no conflicts of interest that are directly related to the content of this study.
- 1.US FDA. Developing orphan products: FDA and Rare Disease Day [FDA Consumer Health Information; online]. Available from URL: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/ucm107301.pdf [Accessed 2009 Aug 19]Google Scholar
- 3.US Department of Health and Human Services. US FDA. Orphan drug product designation database. 2009 [online]. Available from URL: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm [Accessed 2010 Sep 3]Google Scholar
- 5.Dear JW, Lilitkarntakul P, Webb DJ. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol 2006 Sep; 62 (3): 264–71Google Scholar
- 33.Orphanet. Prevalence of rare diseases: bibliographic data. Orphanet Report Series. Orphanet, 2009 [online]. Available from URL: http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf [Accessed 2009 Aug 12]
- 34.Hochhaus A, Berger U, Hehlmann R. Chronische myeloische Leukämie. Empfehlungen zur Diagnostik und Therapie 2. Auflage ed. Bremen: Uni-Med, 2004Google Scholar
- 37.Organisation for Economic Co-operation and Development. PPPs and exchange rates [online]. Available from URL: http://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4 [Accessed 2009 Sep 9]Google Scholar
- 39.US FDA. Full prescribing information: Tyvaso™ (treprostinil) inhalation solution [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022387LBL.pdf [Accessed 2010 May 17]Google Scholar
- 40.Novartis AG. Annual report 2008. Basel: Novartis AG, 2009Google Scholar
- 42.European Commission. Morbus Fabry: Europäische Kommission erteilt erstmals Genehmigung fürzwei Arzneimittel zur Behandlung von seltenen Leiden. Brussels: European Commission, 2001Google Scholar
- 43.National Institute for Health and Clinical Excellence. About NICE guidance: what does it mean for me? Information for patients, carers and the public: an interim guide. 2007 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/AboutGuidance.pdf [Accessed 2010 Sep 3]Google Scholar
- 44.Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) 2003 Jul-Dec; Suppl.Web Exclusives:W3-521-36Google Scholar
- 45.Magazzini L, Pammolli F, Riccaboni M. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur J Health Econ 2004 Jun; 5 (2): 175–82Google Scholar
- 47.Roll K, Stargardt T, Schreyögg J. Authorization and reimbursement of orphan drugs in an international comparison. Gesundheitswesen. Epub 2010 Sep 16Google Scholar